|
European Lessons from U.S. Cannabis Legalization Journey More than €100 million ($116.2 million USD) has been invested in medical cannabis-focused companies across Europe in the past 18 months. |
|
DEA Proposes Dramatic Increase in Marijuana and Psychedelic Production in 2022 Calling for 6,300% More MDMA Alone The DEA is calling for dramatically increased production of cannabis and psychedelics (e.g., psilocybin, LSD, MDMA, and DMT) for research. |
|
Three years in, more than 100 Massachusetts communities have at least 1 licensed cannabis shop The state’s industry has passed $2 billion in sales since 2018, with more than 100 communities having at least one licensed operation. |
|
Analysts Agree: Despite Market Downturn, Cannabis Is 'A Real Opportunity For The Long Term' A NYC panel discussion among cannabis investors pondered whether a current downtrend is a good time to double down on market opportunities.
|
|
Too high to get it right: The effect of cannabis legalization on the performance of cannabis-related stocks A study of Canada’s adult-use legalization from 2015-2020 suggests that it has thus far been unsuccessful from a stock market perspective. |